SAO PAULO: A COVID-19 vaccine developed by China’s Sinovac Biotech was 78% effective in a late-stage Brazilian trial, a person familiar with the study said on Thursday, moving the shot closer to regulatory approval in South America’s biggest country.
The results, closely watched by developing countries counting on the vaccine to begin mass inoculations, come after Turkish researchers said in December that the vaccine showed 91.25% efficacy based on interim data.
Brazil and Indonesia, which have the most COVID-19 cases in Latin America and Southeast Asia respectively, are preparing to roll out the vaccine, called CoronaVac, this month.
Although Coronavac’s efficacy trails the …read more
Source:: The Himalayan Times
